Certified by Founder Lodge
Surveyor Capital
United States - Chicago, Illinois
INVESTOR
1 Disclosed Funding Rounds $100,000,000
35 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
-
Website
https://www.citadel.com/what-we-do/equities/surveyor-capital/
- Contact
- Social Links
Surveyor Capital is a longstanding fundamental equities business at Citadel, established in 2008. Our sector-aligned investment teams conduct deep fundamental research, developing an independ
| Company | Date | Round | Raised |
|---|---|---|---|
 Quanta Therapeutics |
May, 23 ,2023 | Series D | $50,000,000 |
 Aardvark Therapeutics |
May, 10 ,2024 | Series C | $85,000,000 |
 Outpace Bio |
August, 02 ,2024 | Series B | $144,000,000 |
 Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
 Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
 Adcendo |
November, 26 ,2024 | Series B | $135,000,000 |
 Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
 Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Veradermics |
December, 12 ,2024 | Series B | $75,000,000 |
| Quanta Therapeutics |
May, 23 ,2023 | Series D | $50,000,000 |
 Sudo Biosciences |
December, 21 ,2023 | Series B | $116,000,000 |
| Outpace Bio |
August, 02 ,2024 | Series B | $144,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Aardvark Therapeutics |
May, 10 ,2024 | Series C | $85,000,000 |
| Adcendo |
November, 26 ,2024 | Series B | $135,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Veradermics |
December, 12 ,2024 | Series B | $75,000,000 |
| Outpace Bio |
August, 02 ,2024 | Series B | $144,000,000 |
| Sudo Biosciences |
December, 21 ,2023 | Series B | $116,000,000 |
| Adcendo |
November, 26 ,2024 | Series B | $135,000,000 |
| Aardvark Therapeutics |
May, 10 ,2024 | Series C | $85,000,000 |
| Veradermics |
December, 12 ,2024 | Series B | $75,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
 Actithera |
July, 09 ,2025 | Series A | $75,500,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Avenzo Therapeutics |
September, 23 ,2025 | Series B | $60,000,000 |
| Outpace Bio |
August, 02 ,2024 | Series B | $144,000,000 |
| Adcendo |
November, 26 ,2024 | Series B | $135,000,000 |
| Veradermics |
December, 12 ,2024 | Series B | $75,000,000 |
| Actithera |
July, 09 ,2025 | Series A | $75,500,000 |
| Avenzo Therapeutics |
September, 23 ,2025 | Series B | $60,000,000 |
Founderpath
Truework
Finix
Farther
TeamApt Inc.
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
